Controversies regarding choice of vasopressor therapy for management of XXXX in animals.

@entity1 @entity326 @entity935 @entity1425 @entity235 @entity551 @entity591 @entity468 @entity1063
OBJECTIVE: To review and appraise common vasopressor drugs used to treat @entity326 -induced @entity551 in volume replete animals. DATA SOURCES: @entity1 and animal publications were searched using PubMed without time limits and the following keywords were used: "vasopressor," " @entity326 ," " @entity1063 ," " @entity935 ," " @entity1425 ," and "vasopressin." @entity1 DATA SYNTHESIS: The choice of vasopressor drug is unlikely to have a marked impact on outcome, but the incidence of adverse events (eg, @entity591 ) varies greatly between the various treatment options. In agreement with the 2012 Cochrane Database consensus, @entity1063 is the first-choice vasopressor to maintain a mean arterial pressure >= 65 mm Hg. If an additional agent is required, epinephrine should be administered. Low-dose vasopressin can be added to @entity1063 to either increase the arterial blood pressure to the target goal value or decrease the @entity1063 dose, but should not be used as the initial vasopressor. @entity935 is not recommended except in highly selected circumstances. VETERINARY DATA SYNTHESIS: There is insufficient evidence to make definitive conclusions regarding the treatment of naturally occurring @entity326 , but clinical studies are underway to provide further data. CONCLUSIONS: The treatment of @entity551 in @entity1 or animals with @entity326 is challenging and vasopressor therapy is associated with a variety of adverse effects. Further research is warranted in @entity235 and @entity468 to establish evidence-based guidelines.
